Table 2.

Data on mortality based on major vasopressors

Authors Country, YOP Study Design	Intervention Group: Deaths / All (%)	Comparator Group: Deaths / All (%)
Chand et al. USA, 2020 Retrospective [44]	Any vasopressor support: 141 / 233 (61%) Norepinephrine ± other vasopressors: 138 / 226 (61%) Phenylephrine ± other vasopressors: 53 / 89 (60%) Vasopressin ± other vasopressors: 81 / 104 (78%) Epinephrine ± other vasopressors: 19 / 25 (76%)	No vasopressor support: 16 / 67 (24%)
Leisman et al. USA, 2020 Retrospective [52]	Angiotensin-II ± other vasopressors: 4 / 10 (40%)	Other vasopressors: 10 / 19 (53%)
Serpa Neto et al. Multicentric study, 2022 Prospective [50]	Angiotensin-II ± norepinephrine: 35 / 65 (54%)	Other vasopressors: 27 / 67 (40%)
Ofosu-Barko et al. USA, 2021 Retrospective [39]	Angiotensin-II + other vasopressors: 4 / 10 (40%)	-